Ron Kern is a partner in BakerHostetler’s Intellectual Property Group and focuses his practice on patent strategy in the life sciences and pharmaceutical industries. He assists clients in all stages of the development and commercialization of biological products, including evaluating preclinical and clinical results, advising clients of future scientific studies and analyzing the patent portfolios of both client and competitor prior to product launch.
Through due diligence assessments, patent portfolio management and patent prosecution, Ron assists a wide range of clients, including Fortune 500 companies, start-up companies and universities, to enhance and protect their IP rights. He focuses on immunology, molecular biology, microbiology and biochemistry fields, and has extensive experience with a wide range of technologies, including antibody and protein therapeutics, vaccines, gene therapies, immunotherapies and diagnostics.